How to buy Atara Biotherapeutics stock | $13.56

Atara Biotherapeutics, Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 480 staff and has a trailing 12-month revenue of around 0.00.

Atara Biotherapeutics stock price (NASDAQ: ATRA)

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$13.56
52-week range	$11.33 - $26.10
50-day moving average	$14.43
200-day moving average	$15.46
Wall St. target price	$35.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-6.07

Buy Atara Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Atara Biotherapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atara Biotherapeutics price performance over time

Historical closes compared with the close of $13.56 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-14.82%
3 months (2021-04-30)	-3.56%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Atara Biotherapeutics financials

Revenue TTM	$3.6 million
Gross profit TTM	$0
Return on assets TTM	-47.13%
Return on equity TTM	-95.56%
Profit margin	0%
Book value	$4.75
Market capitalisation	$1.1 billion

TTM: trailing 12 months

Shorting Atara Biotherapeutics shares

There are currently 12.1 million Atara Biotherapeutics shares held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 3.7% up from 11.7 million last month.

There are a few different ways that this level of interest in shorting Atara Biotherapeutics shares can be evaluated.

Atara Biotherapeutics's "short interest ratio" (SIR)

Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics shares currently shorted divided by the average quantity of Atara Biotherapeutics shares traded daily (recently around 916927.23823976). Atara Biotherapeutics's SIR currently stands at 13.18. In other words for every 100,000 Atara Biotherapeutics shares traded daily on the market, roughly 13180 shares are currently held short.

However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics shares, or, against the total number of tradable Atara Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Atara Biotherapeutics shares in existence, roughly 140 shares are currently held short) or 0.1979% of the tradable shares (for every 100,000 tradable Atara Biotherapeutics shares, roughly 198 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atara Biotherapeutics.

Find out more about how you can short Atara Biotherapeutics stock.

Atara Biotherapeutics share dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.

Atara Biotherapeutics share price volatility

Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $11.33 up to $26.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.4363. This would suggest that Atara Biotherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.

Frequently asked questions

What percentage of Atara Biotherapeutics is owned by insiders or institutions?
Currently 0.594% of Atara Biotherapeutics shares are held by insiders and 106.828% by institutions. How many people work for Atara Biotherapeutics?
Latest data suggests 480 work at Atara Biotherapeutics. When does the fiscal year end for Atara Biotherapeutics?
Atara Biotherapeutics's fiscal year ends in December. Where is Atara Biotherapeutics based?
Atara Biotherapeutics's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080 What is Atara Biotherapeutics's ISIN number?
Atara Biotherapeutics's international securities identification number is: US0465131078 What is Atara Biotherapeutics's CUSIP number?
Atara Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 046513107